{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:10:25Z","timestamp":1773702625612,"version":"3.50.1"},"reference-count":56,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The respiratory syncytial virus (RSV) is one major cause of lower respiratory tract infections in childhood and an effective vaccine is still not available. We previously described a new rhabdoviral vector vaccine, VSV-GP, a variant of the vesicular stomatitis virus (VSV), where the VSV glycoprotein G is exchanged by the glycoprotein GP of the lymphocytic choriomeningitis virus. Here, we evaluated VSV-GP as vaccine vector for RSV with the aim to induce RSV neutralizing antibodies. Wild-type F (Fwt) or a codon optimized version (Fsyn) were introduced at position 5 into the VSV-GP genome. Both F versions were efficiently expressed in VSV-GP-F infected cells and incorporated into VSV-GP particles. In mice, high titers of RSV neutralizing antibodies were induced already after prime and subsequently boosted by a second immunization. After challenge with RSV, viral loads in the lungs of immunized mice were reduced by 2\u20133 logs with no signs of an enhanced disease induced by the vaccination. Even a single intranasal immunization significantly reduced viral load by a factor of more than 100-fold. RSV neutralizing antibodies were long lasting and mice were still protected when challenged 20 weeks after the boost. Therefore, VSV-GP is a promising candidate for an effective RSV vaccine.<\/jats:p>","DOI":"10.3390\/vaccines7030059","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T11:14:49Z","timestamp":1562152489000},"page":"59","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization"],"prefix":"10.3390","volume":"7","author":[{"given":"Sarah","family":"Wilmschen","sequence":"first","affiliation":[{"name":"Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Schneider","sequence":"additional","affiliation":[{"name":"Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Peters","sequence":"additional","affiliation":[{"name":"Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Bayer","sequence":"additional","affiliation":[{"name":"Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology IZI, 04103 Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Issmail","sequence":"additional","affiliation":[{"name":"Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology IZI, 04103 Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"B\u00e1nki","sequence":"additional","affiliation":[{"name":"Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology IZI, 04103 Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[{"name":"Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5210-7905","authenticated-orcid":false,"given":"Janine","family":"Kimpel","sequence":"additional","affiliation":[{"name":"Division of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"ref_1","first-page":"3","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7683","DOI":"10.1073\/pnas.81.24.7683","article-title":"Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus","volume":"81","author":"Collins","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1099\/jgv.0.000298","article-title":"Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution","volume":"96","author":"Do","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_4","unstructured":"(2017). WHO Strategy to Pilot Respiratory Syncytial Virus Surveillance Based on the Global Influenca Surveillance and Response System (GISRS), World Health Organization."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"The IMpact-RSV Study Group (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102, 531\u2013537.","DOI":"10.1542\/peds.102.3.531"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/vim.2017.0147","article-title":"Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field","volume":"31","author":"Kulkarni","year":"2018","journal-title":"Viral Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: Establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.4049\/jimmunol.1602180","article-title":"Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity","volume":"198","author":"Betancourt","year":"2017","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41467-018-04216-6","article-title":"Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model","volume":"9","author":"Blanco","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1016\/j.vaccine.2015.08.071","article-title":"Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy","volume":"33","author":"Blanco","year":"2015","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jcv.2017.08.017","article-title":"Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal","volume":"95","author":"Chu","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1128\/JVI.73.8.6610-6617.1999","article-title":"Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G","volume":"73","author":"Feldman","year":"1999","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s007050050156","article-title":"Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells","volume":"142","author":"Krusat","year":"1997","journal-title":"Arch. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/viro.2001.1138","article-title":"Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo","volume":"289","author":"Teng","year":"2001","journal-title":"Virology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.1073\/pnas.260499197","article-title":"Structural characterization of the human respiratory syncytial virus fusion protein core","volume":"97","author":"Zhao","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1099\/0022-1317-73-9-2225","article-title":"Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus","volume":"73 Pt 9","author":"Arbiza","year":"1992","journal-title":"J. Gen. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1128\/JVI.03278-12","article-title":"The comparative genomics of human respiratory syncytial virus subgroups A and B: Genetic variability and molecular evolutionary dynamics","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/jvi.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/1348-0421.12365","article-title":"Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus","volume":"60","author":"Sawada","year":"2016","journal-title":"Microbiol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nm1456","article-title":"A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines","volume":"12","author":"Moghaddam","year":"2006","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/jcm.26.8.1595-1597.1988","article-title":"Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity","volume":"26","author":"Murphy","year":"1988","journal-title":"J. Clin. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.vaccine.2018.02.014","article-title":"Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice","volume":"36","author":"Bayer","year":"2018","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1128\/JVI.03276-13","article-title":"VSV-GP: A Potent Viral Vaccine Vector That Boosts the Immune Response upon Repeated Applications","volume":"88","author":"Tober","year":"2014","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bresk, C.A., Hofer, T., Wilmschen, S., Krismer, M., Beierfuss, A., Effantin, G., Weissenhorn, W., Hogan, M.J., Jordan, A.P.O., and Gelman, R.S. (2019). Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. Viruses, 11.","DOI":"10.3390\/v11020159"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1016\/j.vaccine.2007.07.025","article-title":"Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus","volume":"25","author":"Ternette","year":"2007","journal-title":"Vaccine"},{"key":"ref_35","first-page":"480","article-title":"50% end-point calculation","volume":"162","author":"Kaerber","year":"1931","journal-title":"Arch. Exp. Pathol. Pharmakol."},{"key":"ref_36","first-page":"184","article-title":"Effect of respiratory syncytial virus-antibody complexes on cytokine (IL-8, IL-6, TNF-\u03b1) release and respiratory burst in human granulocytes","volume":"82","author":"Arnold","year":"1994","journal-title":"Immunology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12601","DOI":"10.1128\/JVI.01036-09","article-title":"Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus","volume":"83","author":"Kohlmann","year":"2009","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/jvi.71.7.5060-5068.1997","article-title":"Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins","volume":"71","author":"Johnson","year":"1997","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1743-422X-4-51","article-title":"Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps","volume":"4","author":"Ternette","year":"2007","journal-title":"Virol. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11262-010-0449-8","article-title":"Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing","volume":"40","author":"Huang","year":"2010","journal-title":"Virus Genes"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rabinovich, S., Powell, R.L., Lindsay, R.W., Yuan, M., Carpov, A., Wilson, A., Lopez, M., Coleman, J.W., Wagner, D., and Sharma, P. (2014). A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106597"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/JVI.01693-10","article-title":"Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB\/c mice","volume":"85","author":"Stokes","year":"2011","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00189-17","DOI":"10.1128\/JVI.00189-17","article-title":"Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate","volume":"91","author":"Liang","year":"2017","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1128\/JVI.01196-16","article-title":"Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector","volume":"90","author":"Liang","year":"2016","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/viro.1998.9535","article-title":"Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion","volume":"254","author":"Kahn","year":"1999","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/viro.1998.9429","article-title":"A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions","volume":"251","author":"Johnson","year":"1998","journal-title":"Virology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kimpel, J., Urbiola, C., Koske, I., Tober, R., Banki, Z., Wollmann, G., and von Laer, D. (2018). The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. Viruses, 10.","DOI":"10.3390\/v10030108"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Agnandji, S.T., Fernandes, J.F., Bache, E.B., Obiang Mba, R.M., Brosnahan, J.S., Kabwende, L., Pitzinger, P., Staarink, P., Massinga-Loembe, M., and Krahling, V. (2017). Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002402"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1128\/JVI.00235-16","article-title":"Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV","volume":"90","author":"Widjaja","year":"2016","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1128\/JVI.75.22.11079-11087.2001","article-title":"Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge","volume":"75","author":"Kahn","year":"2001","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.imlet.2012.12.005","article-title":"Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice","volume":"150","author":"Johnson","year":"2013","journal-title":"Immunol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11540","DOI":"10.1128\/JVI.02558-08","article-title":"Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain","volume":"83","author":"Ozduman","year":"2009","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e01101-17","DOI":"10.1128\/JVI.01101-17","article-title":"Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F","volume":"91","author":"Liu","year":"2017","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/jmv.21771","article-title":"Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community","volume":"82","author":"Houben","year":"2010","journal-title":"J. Med. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1086\/430008","article-title":"Respiratory syncytial virus load predicts disease severity in previously healthy infants","volume":"191","author":"DeVincenzo","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/jmv.24111","article-title":"The impact of viral dynamics on the clinical severity of infants with respiratory syncytial virus bronchiolitis","volume":"87","author":"Zhou","year":"2015","journal-title":"J. Med. Virol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/3\/59\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:19Z","timestamp":1760187739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/3\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["vaccines7030059"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7030059","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,3]]}}}